DrugPatentWatch Database Preview
Am Regent Company Profile
Email this page to a colleague
See Plans and PricingWhat is the competitive landscape for AM REGENT, and what generic alternatives to AM REGENT drugs are available?
AM REGENT has thirty-four approved drugs.
There are four US patents protecting AM REGENT drugs.
There are sixty patent family members on AM REGENT drugs in thirty-two countries and eighty-three supplementary protection certificates in fourteen countries.
Summary for Am Regent
| International Patents: | 60 |
| US Patents: | 4 |
| Tradenames: | 32 |
| Ingredients: | 30 |
| NDAs: | 34 |
Drugs and US Patents for Am Regent
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Am Regent | INJECTAFER | ferric carboxymaltose | INJECTABLE;INTRAVENOUS | 203565-001 | Jul 25, 2013 | RX | Yes | Yes | 7,612,109 | Start Trial | Y | Y | Start Trial | ||
| Am Regent | CYCLOSPORINE | cyclosporine | INJECTABLE;INJECTION | 065151-001 | Oct 7, 2003 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Am Regent | NEOSTIGMINE METHYLSULFATE | neostigmine methylsulfate | SOLUTION;INTRAVENOUS | 209182-001 | May 4, 2018 | AP | RX | No | No | Start Trial | Start Trial | ||||
| Am Regent | HYDROXYPROGESTERONE CAPROATE | hydroxyprogesterone caproate | SOLUTION;INTRAMUSCULAR | 210723-001 | Jun 21, 2018 | AP | RX | No | No | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Am Regent Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2006505638 | Start Trial |
| Canada | 2635894 | Start Trial |
| South Korea | 20170028449 | Start Trial |
| Peru | 20040571 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Am Regent Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1507558 | 2012/018 | Ireland | Start Trial | PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705 |
| 2712622 | 122017000006 | Germany | Start Trial | PRODUCT NAME: DESMOPRESSIN ODER DAS ACETAT DAVON; NAT. REGISTRATION NO/DATE: 94725.00.00 94726.00.00 20160901 FIRST REGISTRATION: BELGIEN BE497271 BE497280 20160504 |
| 0162036 | 2000C/032 | Belgium | Start Trial | PRODUCT NAME: LEVETIRACETAM; NAT. REGISTRATION NO/DATE: EU/1/00/146/001 20000929; FIRST REGISTRATION: CH 55297 20000329 |
| 2435025 | 2019C/532 | Belgium | Start Trial | PRODUCT NAME: UNE COMBINAISON DE GLYCOPYRROLATE (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI) ET DE FORMOTEROL (INCLUANT LES SELS ACCEPTABLES PHARMACEUTIQUEMENT, LES ESTERS, LES ENANTIOMERES OU LES AUTRES DERIVES DE CECI); AUTHORISATION NUMBER AND DATE: EU/1/18/1339 20181220 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
